Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.38 |
| ▸ | MIF | P14174 | 4/20 | 0.38 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 4/20 | 0.36 |
| ▸ | RARG | P13631 | 4/20 | 0.36 |
| ▸ | RARA | P10276 | 1/20 | 0.36 |
| ▸ | RARB | P10826 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6790423 | 1.00 | CTNNB1 (0.40) | CTNNB1ITGB3ITGA2BAOC3MIF | |
| SCHEMBL6793599 | 0.80 | MIF (0.52) | MIFCYP26A1KDM4EGLA | |
| SCHEMBL6793591 | 0.80 | MIF (0.52) | MIFCYP26A1KDM4EGLA | |
| SCHEMBL8125885 | 0.76 | MAOB (0.56) | MAOBHRH3 | |
| SCHEMBL6792508 | 0.72 | MEN1 (0.70) | CTNNB1AOC3RARGKDM4EHRH3 | |
| SCHEMBL12046659 | 0.70 | KDM4E (0.50) | MIFCYP26A1KDM4EGLA | |
| SCHEMBL6793267 | 0.70 | MEN1 (0.57) | CTNNB1AOC3KDM4EHRH3 | |
| SCHEMBL4815741 | 0.69 | MAOB (0.63) | MAOBHRH3 | |
| SCHEMBL9740545 | 0.68 | MAOB (0.57) | MAOBHRH3 | |
| SCHEMBL30746234 | 0.68 | MPO (0.37) | CTNNB1ITGB3ITGA2BAOC3CYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | CTNNB1 3527/4885ITGB3 4001/4885ITGA2B 3448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.